You are here
Interview with Liz Isenring at MASCC 2016: Ginger - can a purified extract help treat nausea following emetogenic cancer therapy?
Liz Isenring is Professor and Head of Program in the Faculty of Health Services and Medicine at Bond University, Gold Coast, Australia. She gives an overview of a new clinical trial that will evaluate a purified extract of ginger on acute and delayed nausea in patients undergoing chemotherapy. The mechanism of action is not completely understood, but it is known that the rhizome of ginger possesses an array of bioactive compounds (i.e. gingerols, shogaols, zingiberene, zingerone, and paradol) that may be responsible for the reported beneficial effects of ginger use. Prof Isenring reviews how significant nausea is in patients undergoing moderately or highly emetogenic chemotherapy regimens and highlights the significant impact on quality of life due to malnutrition, reduced immune response, cancer-related fatigue, and ultimately on impaired treatment response. This trial will address shortcomings of previous trials using ginger, including optimizing the dose based on the short half-life of ginger and in standardizing the ginger formulation. Also important is the subject’s previous lack of exposure to chemotherapy to eliminate the expectation of nausea.
This interview was recorded at the June 2016 annual meeting of MASCC in Adelaide Australia. It was conducted by medical writer Rhonda Oshanek.